| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/MD.0B013E3182380A76 |
| P698 | PubMed publication ID | 22033451 |
| P50 | author | Manuel Ramos-casals | Q42646201 |
| P2093 | author name string | Xavier Forns | |
| Xavier Bosch | |||
| Albert Bové | |||
| Pilar Brito-Zerón | |||
| Soledad Retamozo | |||
| Roberto Pérez-Alvarez | |||
| Cándido Díaz-Lagares | |||
| BIOGEAS Study Group | |||
| Marta Pérez-de-Lis | |||
| Francisco García-Hernández | |||
| Jose-Maria Sanchez-Tapias | |||
| Leopoldo Lopez-Roses | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| P304 | page(s) | 359-371 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases | |
| P478 | volume | 90 |
| Q34500921 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q57245378 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q38164830 | A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy |
| Q39263506 | A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study |
| Q44596381 | Adalimumab use in patients with psoriasis and hepatitis B: a case series. |
| Q38132273 | Adverse effects of golimumab in the treatment of rheumatologic diseases |
| Q38238948 | Adverse reactions to biologic agents and their medical management. |
| Q42265897 | Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis |
| Q55153984 | Assessment and monitoring of biologic drug adverse events in patients with psoriasis. |
| Q93053160 | Assessment of latent infections in patients receiving biological therapies |
| Q40575142 | Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. |
| Q34311953 | Behcet's Syndrome |
| Q47098502 | Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series |
| Q36298389 | Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. |
| Q45324587 | Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy |
| Q34338096 | Clinical use of anti-TNF therapy and increased risk of infections |
| Q55287694 | Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. |
| Q42234350 | Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project |
| Q92670104 | Controversies in hepatitis C therapy: Reactivation of hepatitis B virus |
| Q37305100 | Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). |
| Q33725615 | Defining quality indicators for best-practice management of inflammatory bowel disease in Canada |
| Q38239127 | HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. |
| Q93140470 | HBV treatment in a patient who will be receiving immunosuppressive therapy |
| Q59355703 | Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver |
| Q38755178 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions |
| Q28076703 | Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened |
| Q36958944 | Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy |
| Q38408897 | Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy |
| Q38805093 | Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals |
| Q39293427 | Hepatitis B reactivation in patients receiving targeted therapies |
| Q54279289 | Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. |
| Q35567748 | Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure |
| Q26784247 | Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations |
| Q39995730 | Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. |
| Q38155954 | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs |
| Q42959718 | Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease |
| Q90648680 | INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids |
| Q42764680 | Immunosuppression in Patients with Chronic Hepatitis B. |
| Q51866366 | Infliximab and occult hepatitis B infection: to treat or not to treat? |
| Q38067127 | Infliximab for the treatment of pediatric ulcerative colitis |
| Q52900365 | Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. |
| Q64897844 | KASL clinical practice guidelines for management of chronic hepatitis B. |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q38084250 | Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases |
| Q34786720 | Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis |
| Q54254957 | Liver Illness and Psoriatic Patients. |
| Q40148112 | Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China |
| Q59352237 | Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients |
| Q26853490 | Management of patients with hepatitis B who require immunosuppressive therapy |
| Q28078157 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection |
| Q38008173 | Management of rheumatic disease with comorbid HBV or HCV infection. |
| Q38947451 | Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). |
| Q91655790 | Medical interventions associated with HBV reactivation: Common and less common |
| Q50894654 | Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. |
| Q38542377 | Occult hepatitis B virus infection in Egypt |
| Q42228747 | Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis |
| Q30251512 | Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. |
| Q38266287 | Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases |
| Q35429416 | Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening |
| Q40830395 | Prevention of HBV reactivation in patients treated with biologic agents. |
| Q26747023 | Prevention of Hepatitis B reactivation in the setting of immunosuppression |
| Q38810735 | Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders |
| Q90608529 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations |
| Q38634826 | Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention |
| Q33872389 | Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? |
| Q38611674 | Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis |
| Q35237316 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. |
| Q44480405 | Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting |
| Q38268598 | Safety considerations when using anti-TNFα therapy to treat Crohn's disease |
| Q40336301 | Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection |
| Q38611360 | Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. |
| Q38161956 | Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update |
| Q40879326 | Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial |
| Q91655817 | Screening for hepatitis B virus to prevent viral reactivation - who and when? |
| Q40345778 | Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation |
| Q36924162 | TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle. |
| Q92810938 | TNF-α polymorphisms affect persistence and progression of HBV infection |
| Q40284619 | The practice pattern of hepatitis b testing in rheumatoid arthritis patients: A cross-national comparison between US and Taiwan. |
| Q37538505 | The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. |
| Q40950014 | The safety and effectiveness of HBV vaccination in patients with juvenile idiopathic arthritis controlled by treatment |
| Q44509047 | The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. |
| Q92627208 | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
| Q94397686 | Tratamiento del VHB en pacientes que van a recibir terapia inmunosupresora |
| Q28084305 | Treatment of rheumatic diseases and hepatitis B virus coinfection |
| Q47546977 | Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice |
| Q44736299 | Tumor necrosis factor inhibitor therapy for hepatitis B virus-infected individuals: How loud is the alarm bell? |
| Q36302689 | Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model |
| Q33927761 | Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model |
| Q57183330 | Update on Vaccinating the Patient With Inflammatory Bowel Disease |
| Q38084182 | Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. |
| Q52884662 | [Anticytokine therapy]. |
Search more.